Replies to post #182630 on Biotech Values

[DewDiligence]

MNTA/BAX—CTA for M923 (Humira FoB) accepted by UK, triggering $12M milestone payment from BAX to MNTA and allowing a phase-1 trial of M923 to start immediately:

http://finance.yahoo.com/news/momenta-pharmaceuticals-announces-acceptance-clinical-130000081.html

Nuance: Today’s PR says MNTA expects to receive the $12M in 4Q14; prior guidance was for receipt in 4Q14 or 1Q15.